Cariprazine, a new, orally active dopamine D2/3receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cariprazine, a new, orally active dopamine D2/3receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 13, Issue 11, Pages 1141-1159
Publisher
Informa UK Limited
Online
2013-11-01
DOI
10.1586/14737175.2013.853448
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alternative pharmacologic targets for the treatment of schizophrenia
- (2013) Seiya Miyamoto et al. CURRENT OPINION IN PSYCHIATRY
- Direct and indirect interactions of the dopamine D3 receptor with glutamate pathways: implications for the treatment of schizophrenia
- (2013) Pierre Sokoloff et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors
- (2012) Éva Ágai-Csongor et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Effect of Aripiprazole on Verbal Memory and Fluency in Schizophrenic Patients
- (2012) Chris Bervoets et al. CNS DRUGS
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
- (2012) S Miyamoto et al. MOLECULAR PSYCHIATRY
- Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats
- (2012) V. Román et al. PSYCHOPHARMACOLOGY
- Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse
- (2012) Ross Zimnisky et al. PSYCHOPHARMACOLOGY
- P03-185 - The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia
- (2011) A. Bose et al. EUROPEAN PSYCHIATRY
- Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients
- (2011) Norio Yasui-Furukori et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents
- (2011) István Gyertyán et al. NEUROCHEMISTRY INTERNATIONAL
- Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography
- (2011) Nicholas Seneca et al. PSYCHOPHARMACOLOGY
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- P.2.e.037 The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial
- (2009) M. Knesevich et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients
- (2009) S. Potkin et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The 'atypicality' of antipsychotics: a concept re-examined and re-defined
- (2009) Gerhard Gründer et al. NATURE REVIEWS DRUG DISCOVERY
- Definitions of response and remission in schizophrenia: recommendations for their use and their presentation
- (2008) S. Leucht et al. ACTA PSYCHIATRICA SCANDINAVICA
- P.3.c.051 Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers
- (2008) M. Kapás et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- P.3.d.015 Pharmacokinetics of RGH-188, a novel dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in rats and dogs
- (2008) G. Pásztor Mészáros et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- RGH-188, a d3/d2 dopamine receptor antagonist/partial agonist atypical antipsychotic candidate
- (2008) I. Laszlovszky et al. EUROPEAN PSYCHIATRY
- Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15
- (2008) István Gyertyán et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15
- (2008) Béla Kiss et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started